Source: RT360

The Spanish health watchdog has said it sees no reason to stop the use of hydroxychloroquine (HCQ).

Several European nations, including France, Italy and Belgium, have decided to suspend prescription of the anti-malaria drug, which came to international prominence after the US President said the medicine could be used to tackle Covid-19 and that he himself was taking it.

The Spanish health watchdog, AEMPS, said the paper published by the magazine Lancet, which warned about health risks associated with HCQ, was not conclusive enough to stop testing it at Spanish hospitals. “It is an observational study, not a clinical trial,” a spokesman for AEMPS explained.

HCQ, which is also used to treat autoimmune diseases like lupus, has been widely prescribed in Spain to Covid-19 patients, with the country enduring one of the worst outbreaks of the disease in Europe. According to El Pais, 85 percent of patients taken to hospital with the coronavirus received the medicine.



Related: Hydroxychloroquine: Turkey continues using drug despite WHO pause





Related: Anti-malarial drug hydroxychloroquine drug does help 91 per cent of COVID-19 patients, claim US doctors

blank
Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »